Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning
Shannon R. McCurdy(Hospital of the University of Pennsylvania), Leo Luznik(Johns Hopkins University), Jonathan D. Powell(Enzo Life Sciences (United States)), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Kenneth R. Cooke(Johns Hopkins University), Vedran Radojčić(University of Utah), Hua‐Ling Tsai(Johns Hopkins University), Sophie Paczesny(MUSC Hollings Cancer Center), Djamilatou Adom(National Institutes of Health), Ante Vulic(Johns Hopkins University), Ravi Varadhan(Johns Hopkins University), Brian K. Lohman, Christopher G. Kanakry(National Cancer Institute), Heather J. Symons(Johns Hopkins University), Elizabeth D. Thompson(Johns Hopkins University), Sanja Ivčević(University of Utah)
Cited by 100
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
|Nature Immunology|2011|1.1k
Frailty in Older Adults: A Nationally Representative Profile in the United States
|The Journals of Gerontology Series A|2015|789
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases
|Frontiers in Immunology|2017|612
The physical frailty syndrome as a transition from homeostatic symphony to cacophony
|Nature Aging|2021|565